Prostate cancer prevented with selenium accumulation in prostate tissue
Prostate cancer could be prevented with oral selenium supplementation due to preferential accumulation in prostate tissue rather than the seminal vesicle (SV).
According to recent research published in the journal Clinical Cancer Research, "Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue."
"We conducted a randomized, controlled, short-term trial of I-selenomethionine (SeMet) versus observation in men with organ-confined prostate cancer The primary endpoint was the measurement of selenium concentration in prostate tissue and SV," explained A.L. Sabichi and colleagues, M.D. Anderson Cancer Center. "We assessed baseline selenium levels in serum and in toenail specimens (reflecting long-term intake) and post-intervention selenium levels in serum, and in prostate and SV tissues using hydride generation atomic fluorescence spectroscopy."
"Sixty-six eligible patients were randomly assigned to the SeMet (n4) or observation (n2) arm; both arms had similar baseline patient characteristics Baseline serum selenium was similar in the two groups (p=.64). Baseline toenail selenium levels were slightly higher in the SeMet group than in the control group (p=.07).
"After the intervention, the mean serum selenium level increased 15% in the SeMet arm and was higher than in the observation arm (p=.001). The selenium concentration in prostate tissue was 22% higher in the SeMet arm (n&) than in the observation arm (n%; 1.80 versus 147 ppm; p=.003, Wilcoxon rank sum test) and remained significantly higher after adjusting for chronic selenium intake (p=.021, ANCOVA). SV selenium concentration was similar in both groups (p=.384) and was lower than in prostate tissue," found the investigators.
The researchers concluded, "The present study is the first to show that selenium taken as oral supplementation accumulates preferentially in the human prostate gland as opposed to the SV. These findings support the hypothesis that oral selenium supplementation may contribute to the cancer preventive effects of selenium."
Sabichi and colleagues published their study in Clinical Cancer Research (Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group study. Clin Cancer Res, 2006;12(7 Part 1):2178-2184).
For additional information, contact A.L. Sabichi, University of Texas, M.D. Anderson Cancer Center, Dept. Clinic Cancer Prevention, 1515 Holcombe Blvd., POB 301439, Unit 1360, Houston, TX 77230, USA.
The publisher's contact information for the journal Clinical Cancer Research is: American Association Cancer Research, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404, USA.
Keywords: Houston, Texas, United States, Oral Selenium Supplementation, Chemoprevention, Cancer Prevention, Epidemiology, Men's Health, Oncology, Prostate Cancer, Prostate Carcinoma. This article was prepared by Biotech Week editors from staff and other reports. Copyright 2006, Biotech Week via NewsRx.com.
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com.